Study may lead to new CF treatments.
Published: March 20, 2008 at 12:25 PM
TORONTO, March 20 (UPI) -- Canadian scientists said a study identifying several compounds that block activity of a key protein might lead to innovative cystic fibrosis therapies.
The University of Toronto researchers said their findings might also serve as a model for future therapies against the human immunodeficiency virus.
A team led by Professor Igor Stagljar identified compounds that block activity of the protein exoenzymeS. One compound, exosin, significantly inhibited infections in mammalian cells, showing promise for increasing the effectiveness of antibiotics in the treatment of chronic and acute bacterial respiratory infections in cystic fibrosis patients.
"These studies created a road map to the rational design of more potent, highly selective inhibitors against other similar toxins using a totally novel yeast-based approach," Stagljar said. "This innovative approach is an important advance, not only for the value it may have in cystic fibrosis treatment, but also because this technique could be used to design novel therapies for any bacterial pathogen as well as the HIV virus."
The scientists now plan to test the action of their inhibitors in an animal model of cystic fibrosis.
The research that included graduate student Anthony Arnoldo is detailed in the online edition of the journal PLoS Genetics.
The University of Toronto researchers said their findings might also serve as a model for future therapies against the human immunodeficiency virus.
A team led by Professor Igor Stagljar identified compounds that block activity of the protein exoenzymeS. One compound, exosin, significantly inhibited infections in mammalian cells, showing promise for increasing the effectiveness of antibiotics in the treatment of chronic and acute bacterial respiratory infections in cystic fibrosis patients.
"These studies created a road map to the rational design of more potent, highly selective inhibitors against other similar toxins using a totally novel yeast-based approach," Stagljar said. "This innovative approach is an important advance, not only for the value it may have in cystic fibrosis treatment, but also because this technique could be used to design novel therapies for any bacterial pathogen as well as the HIV virus."
The scientists now plan to test the action of their inhibitors in an animal model of cystic fibrosis.
The research that included graduate student Anthony Arnoldo is detailed in the online edition of the journal PLoS Genetics.
© 2008 United Press International. All Rights Reserved.
This material may not be reproduced, redistributed, or manipulated in any form.
This material may not be reproduced, redistributed, or manipulated in any form.
» Next in Science:
Older blood increases heart surgery risks
This undated NASA image shows two galaxies that are slowly colliding and possibly, in hundreds of millions of years, only one galaxy will remain. Although it is likely that no stars in the two galaxies will directly collide, the gas, dust and ambient magnetic fields do interact directly. These galaxies, part of the vast Hydra-Centaurus supercluster of galaxies, spans over 100 thousand light-years across and is located about 100 million light-years away. (UPI Photo/NASA/ESA/Hubble Heritage)
NASA image shows galaxies that will slowly collide
Full Photo
| Slideshow
Latest Headlines
Most Popular
- New York teachers learn cell phone lessons
- Florida deputy bitten by gator
- Arrest in 1991 'Point Break' robbery
- Thong helps Giambi out of slumps
- Woman with large cyst told to lose weight
- Bus group wants 'gentler' female drivers
- Man claimed real benefits for fake kids
- East German clunker headed to Olympics